Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00033 / http://dx.doi.org/10.20960/revcancer.00033

Resumen| PDF

Revisión

Cáncer de mama triple negativo: segunda y sucesivas líneas de tratamiento

Fernando Henao Carrasco, Sara Leal Sánchez

Prepublicado: 2023-07-12

Publicado: 2023-07-12

VOLUMEN 37, NÚM. 1, enero-febrero (2023), PAG. 8-16

Logo Descargas Número de descargas: 59371 Logo Visitas Número de visitas: 1659 Citas Citas: 0

Compártelo:

El cáncer de mama metastásico triple negativo constituye en la actualidad un reto en la consulta de oncología de cáncer de mama. Tradicionalmente la quimioterapia en monoterapia de manera secuencial ha sido el tratamiento estándar en segunda y sucesivas líneas. En la actualidad estamos asistiendo a una revolución terapéutica con la aparición de nuevas terapias, como la inmunoterapia o los anticuerpos conjugados, así como combinaciones de ambos, que están consiguiendo incrementos en supervivencia en una enfermedad que, por desgracia, sigue siendo de mal pronóstico desde el momento del diagnóstico. La aparición de nuevos fármacos diana y de nuevas vías de alteración molecular suponen la introducción de nuevos estándares de tratamiento en líneas avanzadas de la enfermedad. En los próximos años muy probablemente asistiremos a una ampliación en las posibilidades de tratamiento y a un cambio en la secuencia óptima de tratamiento gracias a la aparición de estos nuevos fármacos.

Palabras Clave: Cáncer de mama metastásico. Triple negativo. Anticuerpos conjugados. Sacituzumab govitecán. Quimioterapia.

Descargar PDF

Bibliografía
Artículos Relacionados

Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl) 2016;10:25-36.
DOI: 10.4137/BCBCR.S32783

Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast 2017;31:244-59.
DOI: 10.1016/j.breast.2016.10.001

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 5. 2020 July 15.

Pérez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2- negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010;121:261-71.
DOI: 10.1007/s10549-010-0824-0

Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;133:1067-75.
DOI: 10.1007/s10549-012-2008-6

Pivot X, Marmé F, Koenigsberg R, et al. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 2016;27:1525-31.
DOI: 10.1093/annonc/mdw203

Park IH, Im S-A, Jung KH, et al. Ran- domized open label phase III trial of irinotecan plus capecitabine versus capecita- bine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01). Cancer Res Treat 2019;51:43-52.
DOI: 10.4143/crt.2017.562

Cortés J, Lipatov ON, Im S-A, et al. KEYNOTE-119: phase III study of pem- brolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol 2019;30(Suppl.5):859-60.
DOI: 10.1093/annonc/mdz394.010

Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2022;386:942-50.
DOI: 10.1056/NEJMoa2114663

Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011;13:17.
DOI: 10.1007/s11912-010-0137-9

Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol 2010;28S:ASCO #1007.
DOI: 10.1200/jco.2010.28.15_suppl.1007

Bardia A, Tolaney SM, Loirat D, et al. ASCENT: A randomized phase III study of sacituzumab govitecán (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann Oncol 2020;31(Suppl.4):S1142-215.
DOI: 10.1016/j.annonc.2020.08.2245

Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC5). Ann Oncol 2020;31(12):1623-49.
DOI: 10.1016/j.annonc.2020.09.010

García-Sáenz JA, Blancas I, Echavarria I, et al. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer. (2022) Clin Trasl Oncology 2023 May 6.
DOI: 10.1007/s12094-023-03203-8

Andersson M, Daugaard S, von der Maase H, et al. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. Cancer Treat Rep 1986;70:1181.

Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000;18:2385.
DOI: 10.1200/JCO.2000.18.12.2385

Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998;16:3720.
DOI: 10.1200/JCO.1998.16.12.3720

Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 22:2313.
DOI: 10.1200/JCO.2004.11.503

Nielsen D, Dombernowsky P, Larsen SK, et al. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 2000;46:459.
DOI: 10.1007/s002800000178

O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440.
DOI: 10.1093/annonc/mdh097

Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22:3893.
DOI: 10.1200/JCO.2004.08.157

Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998;25:43.

Manso L, Moreno Antón F, Izarzugaza Perón Y, et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J 2019;25:219.
DOI: 10.1111/tbj.13199

Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015;33:594.
DOI: 10.1200/JCO.2013.52.4892

Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914.
DOI: 10.1016/S0140-6736(11)60070-6

Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer 2019;112:57.
DOI: 10.1016/j.ejca.2019.02.002

Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397.
DOI: 10.1023/A:1008364222793

Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219.
DOI: 10.1016/S1470-2045(07)70041-4

Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245.
DOI: 10.1200/JCO.1993.11.7.1245

Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567.
DOI: 10.1200/JCO.1995.13.10.2567

Cazzaniga ME, Cortesi L, Ferzi A, et al. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast CAncer Res Treat 2016;106(3):501-9.
DOI: 10.1007/s10549-016-4009-3

Gridelli C, Perrone F, Gallo C, et al. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res 1999;19:4535.

Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 90:215.
DOI: 10.1007/s10549-004-2468-4

Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002;62:2.
DOI: 10.1159/000048240

Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005;16:899.
DOI: 10.1093/annonc/mdi181

Pérez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407.
DOI: 10.1200/JCO.2006.09.3849

European Medicines Agency Committee for Medicinal Products for Human Use. Recommendation for refusal of marketing authorization for ixabepilone [acceso: 21 de septiembre de 2017). Disponible en: http://www.esmo.org/no_cache/view-news.html?tx_ttnews[tt_news]=480&tx_ttnews[backPid]=585&cHash=9385b0342b

Martín M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986.
DOI: 10.1200/JCO.1994.12.5.986

Pusztai L, Walters RS, Valero V, et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 1998;21:442.
DOI: 10.1097/00000421-199810000-00004

Saphner T, Weller EA, Tormey DC, et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol 2000;23:258.
DOI: 10.1097/00000421-200006000-00010

Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53.
DOI: 10.1097/PPO.0b013e3181d24ff7

Vernieri C, Prisciandaro M, Milano M, et al. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. Clin Breast Cancer 2019;19(2):e306-18.
DOI: 10.1016/j.clbc.2018.12.004

De la Cruz-Merino L, Gion M, Cruz-Jurado J, et al. Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers (Basel) 2021;13(21):5432.
DOI: 10.3390/cancers13215432

Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017;377:523.
DOI: 10.1056/NEJMoa1706450

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018;379(8):753-63.
DOI: 10.1056/NEJMoa1802905

González-Santiago S, Ramón y Cajal T, Aguirre E, et. Al SEOM Clincal guidelines in hereditary breast and ovarian cancer (2019). Clin Transl Oncol 2020;22:193-200.
DOI: 10.1007/s12094-019-02262-0

Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple- negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24:628.
DOI: 10.1038/s41591-018-0009-7

Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022;387:9.
DOI: 10.1056/NEJMoa2203690

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento sistémico del cáncer en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Manejo del linfoma agresivo del paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de colon en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF